Publication:
Impact Of Timely Bcr-abl1 Monitoring Before Allogeneic Stem Cell\r\nTransplantation Among Patients With Bcr-abl1-positive B-acute\r\nLymphoblastic Leukemia

Simple item page
dc.contributor.authorSiew Lian Chongen_US
dc.contributor.authorProf. Madya Dr. Asral Wirda Binti Ahmad Asnawien_US
dc.contributor.authorTze Shin Leongen_US
dc.contributor.authorJenq Tzong Tanen_US
dc.contributor.authorKian Boon Lawen_US
dc.contributor.authorSiong Leng Honen_US
dc.contributor.authorRui Jeat Fannen_US
dc.contributor.authorSen Mui Tanen_US
dc.date.accessioned2024-05-27T14:34:22Z
dc.date.available2024-05-27T14:34:22Z
dc.date.issued2021
dc.date.submitted2022-1-27
dc.descriptionBlood Res 2021; 56(3): 175-183 https://doi.org/10.5045/br.2021.2021045en_US
dc.description.abstractBackground With the emergence of tyrosine kinase inhibitors and the incorporation of stringent measurable residual disease (MRD) monitoring, risk stratification for BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients has changed significantly. However, whether this monitoring can replace conventional risk factors in determining whether patients need allogeneic stem cell transplantation is still unclear. This study aimed to determine the impact of BCR-ABL1 monitoring on the outcome of patients with BCR-ABL1-positive ALL after allogeneic stem cell transplantation. Methods We retrospectively analyzed the survival outcome of patients with BCR-ABL1-positive ALL based on the quantification of BCR-ABL1 at 3 timepoints: the end of induction (timepoint 1), post-consolidation week 16 (timepoint 2), and the end of treatment for patients who were either transplant-eligible or non-transplant eligible (timepoint 3). Results From 2006 to 2018, a total of 96 patients newly diagnosed with BCR-ABL1-positive ALL were treated with chemotherapy and tyrosine kinase inhibitors. Thirty-eight (41.3%) patients achieved complete remission, and 33 patients underwent allogeneic stem cell transplantation. Our data showed that pre-transplant MRD monitoring by real-time quantitative polymerase chain reaction had the highest correlation with survival in patients with BCR-ABL1-positive ALL, especially for those who underwent allogeneic stem cell transplantation. Conclusion Patients without MRD pre-transplantation had superior survival compared with those who had MRD, and they had excellent long-term outcomes after allogeneic stem cell transplantation.en_US
dc.identifier.citationChong, Siew & Asnawi, Asral & Leong, Tze & Tan, Jenq & Law, Kian Boon & Hon, Siong & Rui Jeat, Fann & Tan, Sen Mui. (2021). Impact of timely BCR-ABL1 monitoring before allogeneic stem cell transplantation among patients with BCR-ABL1 -positive B-acute lymphoblastic leukemia. BLOOD RESEARCH. 56. 10.5045/br.2021.2021045.en_US
dc.identifier.doihttps://doi.org/10.5045/br.2021.2021045
dc.identifier.epage183
dc.identifier.issn2288-0011
dc.identifier.issue3
dc.identifier.other597-23
dc.identifier.spage175
dc.identifier.urihttps://www.bloodresearch.or.kr/journal/view.html?doi=10.5045/br.2021.2021045
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/3179
dc.identifier.volume56
dc.language.isoenen_US
dc.publisherKorean Society of Hematologyen_US
dc.relation.ispartofBlood Researchen_US
dc.subjectALL, BCR-ABL1, Philadelphia, Survival, TKIen_US
dc.titleImpact Of Timely Bcr-abl1 Monitoring Before Allogeneic Stem Cell\r\nTransplantation Among Patients With Bcr-abl1-positive B-acute\r\nLymphoblastic Leukemiaen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Impact of timely BCR-ABL1 monitoring before allogeneic stem cell transplantation among patients with BCR-ABL1-positive B-acute lymphoblastic leukemia.pdf
Size:
590.18 KB
Format:
Adobe Portable Document Format
Download

Collections

Other Publications